Emerging therapy for the treatment of mantle cell lymphoma.

J Natl Compr Canc Netw

From the Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin.

Published: September 2014

Mantle cell lymphoma (MCL) is a heterogenous disease with historically relative poor outcomes. However, new treatment strategies seem to be improving the prognosis for patients. Although no universally accepted standard of care exists, options for patients with newly diagnosed MCL include intensive and nonintensive strategies. Generally, intensive strategies produce more durable remissions and are selected for younger patients, whereas nonintensive strategies are most appropriate for older patients or patients with comorbidities. However, new options are closing the treatment gap between intensive and nonintensive strategies. Treatment options are also increasing for patients with relapsed/refractory MCL and include agents targeting the microenvironment and the B-cell receptor signaling pathway.

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0126DOI Listing

Publication Analysis

Top Keywords

nonintensive strategies
12
mantle cell
8
cell lymphoma
8
mcl include
8
intensive nonintensive
8
patients
6
strategies
5
emerging therapy
4
treatment
4
therapy treatment
4

Similar Publications

Background/objectives: Sepsis is a life-threatening condition characterized by an imbalanced immune response to infection, posing a significant challenge in hospital settings due to its high morbidity and mortality rates. While much attention has been given to patients in the ICU, uncertainties remain regarding the nutritional management of septic patients in non-intensive wards. This narrative review aims to address these gaps by exploring key aspects of nutritional care in sepsis patients admitted to non-intensive wards.

View Article and Find Full Text PDF

Impact of intensive versus nonintensive antithrombotic treatment on device-related thrombus after left atrial appendage closure.

Rev Esp Cardiol (Engl Ed)

December 2024

Institut Clínic Cardiovascular (ICCV), Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Introduction And Objectives: The optimal antithrombotic therapy (AT) after left atrial appendage closure (LAAC) is debated. We assessed the impact of intensive vs nonintensive AT on the incidence of device-related thrombus (DRT) based on whether the device implantation was classified as optimal or suboptimal.

Methods: This study included patients who underwent successful LAAC in 9 centers.

View Article and Find Full Text PDF

(1) Background: Helmet Continuous Positive Airway Pressure (H-CPAP) has primarily been used in intensive care settings to treat moderate-to-severe bronchiolitis in infants. We aim to report on the feasibility of H-CPAP for selected infants with bronchiolitis in a pediatric ward. (2) Methods: A retrospective, observational, consecutive case series was studied of 26 patients who received H-CPAP on the pediatric ward from October 2022 to February 2023, including a description of patient outcomes and costs.

View Article and Find Full Text PDF
Article Synopsis
  • * Non-invasive ventilation (NIV) and high-flow nasal cannula oxygen therapy (HFNC) provide necessary respiratory support during these procedures.
  • * A successful case study involving a 78-year-old patient with ARF showed that combining HFNC with multiple FBOs improved his condition and allowed similar treatments for other ARF patients, suggesting this combination could be a safe alternative to intubation in elderly patients facing severe airway obstruction.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!